Dividend To Observe: Nov 15, 2016 is the day that Abbott Laboratories (NYSE:ABT) claims $0.26 dividends could be paid.

Dividend To Observe: Nov 15, 2016 is the day that Abbott Laboratories (NYSE:ABT) claims $0.26 dividends could be paid.

Abbott Laboratories (NYSE:ABT) is expected to pay $0.26 on Nov 15, 2016. The indicated annual dividend is $1.04. Shareholders owning the stock before Oct 12, 2016 will be eligible to receive the payout. Based on Abbott Laboratories’s current price of $43.50, the dividend is 0.60%. This dividend’s record date is Oct 14, 2016 and the announcement date is Sep 16, 2016. The stock increased 1.23% or $0.53 during the last trading session, hitting $43.5. Abbott Laboratories (NYSE:ABT) has risen 11.05% since March 8, 2016 and is uptrending. It has outperformed by 1.74% the S&P500.

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The company has a market cap of $63.94 billion. The Firm operates in four business divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. It has a 33.39 P/E ratio. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products.

Insitutional Activity: The institutional sentiment increased to 1.05 in 2016 Q2. Its up 0.18, from 0.87 in 2016Q1. The ratio improved, as 68 funds sold all Abbott Laboratories shares owned while 488 reduced positions. 79 funds bought stakes while 507 increased positions. They now own 1.05 billion shares or 2.91% more from 1.02 billion shares in 2016Q1.
Zuckerman Invest Group Inc Limited Liability Company accumulated 0.8% or 76,541 shares. Fdx Advsr holds 0.08% or 43,057 shares in its portfolio. Ar Asset has invested 0.14% of its portfolio in Abbott Laboratories (NYSE:ABT). Carnegie Capital Asset Mgmt Ltd Liability Corporation holds 48,146 shares or 0.3% of its portfolio. Moreover, Camarda Fincl Advisors Ltd Liability Com has 0.01% invested in Abbott Laboratories (NYSE:ABT) for 289 shares. Creative Planning owns 206,062 shares or 0.06% of their US portfolio. Salem Invest Counselors accumulated 0.35% or 74,622 shares. Riverhead Cap Mgmt Ltd Liability Com has invested 2.77% of its portfolio in Abbott Laboratories (NYSE:ABT). Inv Advsr Limited Liability last reported 0.03% of its portfolio in the stock. Rodgers Brothers Inc accumulated 117,936 shares or 1.91% of the stock. The United Kingdom-based Polar Capital Llp has invested 0.11% in Abbott Laboratories (NYSE:ABT). Neuberger Berman Gru Ltd Llc accumulated 4.87M shares or 0.26% of the stock. Maryland Management reported 453,675 shares or 2.81% of all its holdings. Lvm Capital Ltd Mi holds 0.38% or 33,475 shares in its portfolio. Bedrijfstakpensioenfonds Voor De Media Pno has 23,500 shares for 0.12% of their US portfolio.

Insider Transactions: Since April 28, 2016, the stock had 1 buy, and 8 sales for $6.08 million net activity. The insider WHITE MILES D bought 242,547 shares worth $10.47 million. On Thursday, July 28 the insider Fussell Stephen R sold $1.87M. Another trade for 565 shares valued at $22,312 was made by YOOR BRIAN B on Wednesday, June 1. Warmuth Michael J had sold 26,800 shares worth $1.17 million on Tuesday, July 26. 815 Abbott Laboratories (NYSE:ABT) shares with value of $33,994 were sold by Salvadori Daniel Gesua Sive. Funck Robert E also sold $1.15M worth of Abbott Laboratories (NYSE:ABT) on Monday, July 25. Watkin Jared sold $20,770 worth of Abbott Laboratories (NYSE:ABT) on Wednesday, June 15.

Abbott Laboratories (NYSE:ABT) Ratings Coverage

Out of 16 analysts covering Abbott Laboratories (NYSE:ABT), 9 rate it a “Buy”, 0 “Sell”, while 7 “Hold”. This means 56% are positive. $90 is the highest target while $9 is the lowest. The $48.83 average target is 12.25% above today’s ($43.5) stock price. Abbott Laboratories has been the topic of 40 analyst reports since July 24, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Edward Jones given on Tuesday, June 21. As per Monday, August 10, the company rating was reinitiated by Credit Suisse. The firm earned “Buy” rating on Tuesday, March 15 by Jefferies. Jefferies maintained it with “Buy” rating and $45 target price in Tuesday, June 14 report. Deutsche Bank maintained the stock with “Buy” rating in Saturday, August 29 report. Goldman Sachs downgraded the stock to “Neutral” rating in Friday, November 13 report. The rating was downgraded by Piper Jaffray to “Neutral” on Thursday, April 28. The firm earned “Buy” rating on Saturday, August 29 by BTIG Research. On Tuesday, September 13 the stock rating was maintained by Jefferies with “Buy”. The stock of Abbott Laboratories (NYSE:ABT) earned “Buy” rating by Stifel Nicolaus on Thursday, July 23.

More notable recent Abbott Laboratories (NYSE:ABT) news were published by: Cnbc.com which released: “Johnson & Johnson to buy Abbott Medical Optics for $4.33 billion in cash” on July 22, 2016, also Nasdaq.com with their article: “Ex-Dividend Reminder: Abbott Laboratories, PerkinElmer and Mid-America …” published on October 10, 2016, Reuters.com published: “EU ruling on $25 billion Abbott, St. Jude deal due by November 9” on October 04, 2016. More interesting news about Abbott Laboratories (NYSE:ABT) were released by: Thestreet.com and their article: “Johnson & Johnson (JNJ) Stock Lower, Buys Abbott Laboratories’ Medical Optics …” published on September 16, 2016 as well as Reuters.com‘s news article titled: “BRIEF-Terumo Corp looks to purchase portion of Abbott Laboratories’ medica…” with publication date: September 29, 2016.

ABT Company Profile

Abbott Laboratories (Abbott), incorporated on March 6, 1900, is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Firm operates in four business divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Nutrition Products segment includes the sales of a line of adult and pediatric nutritional products. The Diagnostic Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment